New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:58 EDTOMER, MRK, RL, COCO, DATA, XONE, DDD, CTSH, VJET, SSYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Merck (MRK), up 1.6%... Ralph Lauren (RL), up 7%... Tableau Software (DATA), up 12%... Corinthian Colleges (COCO), up 2%. ALSO HIGHER: Omeros (OMER), up 11% after granted fast track designation to OMS824 by FDA. DOWN AFTER EARNINGS: Allergan (AGN), down xx%... Cognizant (CTSH), down 5%. ALSO LOWER: 3D Systems (DDD), down 15% after lowering FY13 EPS view, guiding FY14 below estimates. Peers Stratasys (SSYS), down 7.5%, ExOne (XONE), down 8%, and Voxeljet (VJET), down 7%, lower as well.
News For DDD;RL;SSYS;XONE;MRK;VJET;DATA;OMER;CTSH;COCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 23, 2015
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
16:21 EDTCOCOCorinthian Colleges subsidiary files for Canadian bankruptcy protection
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:20 EDTDDD3D Systems implied volatility of 68 at upper end of index mean range
Subscribe for More Information
February 19, 2015
10:12 EDTDDD3D Systems price target lowered to $36 from $42 at Imperial Capital
Imperial Capital lowered its price target for 3D Systems shares to $36 ahead of the company's Q4 results but keeps an Outperform rating on the name. The firm views lower organic growth rates and declining margins as near-term headwinds.
09:12 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
07:37 EDTSSYSStratasys core business remains solid, says Canaccord
Subscribe for More Information
07:17 EDTOMEROmeros's Phase 2 OMS721 trial shows positive results
Subscribe for More Information
05:35 EDTDDD3D Systems implied volatility of 73 at upper end of index mean range
Subscribe for More Information
February 18, 2015
16:04 EDTXONEExOne announces six new printable materials for use in 3D printing systems
ExOne announced that six additional materials are now printable in the company's printing systems: Cobalt-Chrome, IN Alloy 718, Iron-Chrome-Aluminum, 17-4 Stainless Steel, 316 Stainless Steel and Tungsten Carbide. Using ExOne's printing systems – including the M-Flex and recently introduced Innovent– customers interested in 3D printing materials for their own product development are afforded the opportunity to utilize the wide variety of new materials, each offering unique properties and uses. These qualified materials are distinguishable from printable materials in that they are commercially available for sale in industrial densities or for finished products printed at an ExOne PSC. ExOne manufactures and sells direct and indirect printing systems as well as printable and qualified materials, binder, cleaner and other consumables for use in its machines.
11:54 EDTVJET, XONE, DDD, SSYSAnalyst says Barron's thesis on 3D printing stocks outdated
Subscribe for More Information
10:42 EDTRLApparel makers beyond Perry Ellis seen hurt by port slowdown
Subscribe for More Information
08:04 EDTSSYS, XONE, DDDBarron's wrong on 3D printing stocks, says Oppenheimer
Subscribe for More Information
06:43 EDTDDD3D Systems volatility increases into Q4 and outlook
3D Systems February call option implied volatility is at 78, February weekly is at 99, March is 76, May is at is at 52; compared to its 26-week average of 47 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on February 26.
05:59 EDTDDD3D Systems implied volatility of 71 at upper end of index mean range
Subscribe for More Information
February 17, 2015
18:43 EDTRLApparel stocks lower after Perry Ellis warns of West Coast port disruption
Subscribe for More Information
07:11 EDTDDD3D Systems volatility elevated into Q4 and outlook
Subscribe for More Information
February 15, 2015
17:26 EDTDDD3D Systems could continue to fall, Barron's says
Investors should not view 3D Systems' current drop as an opportunity as shares could continue to fall to $15 per share, Barron's contends in a follow up article. Reference Link
17:10 EDTCOCOCalifornia suspends Cal Grants to Corinthian’s Heald students
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use